sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
Published 1 year ago • 165 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
2:06
the optimal sequencing of car-t and other immunotherapies in multiple myeloma
-
1:24
bispecifics & cars: bcma, gprc5d & fcrh5 sequencing
-
1:55
optimal sequencing of car-t and bispecifics in nhl
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
58:36
bispecific antibodies in multiple myeloma
-
5:06
bispecific antibodies: late side effects
-
3:20
bispecific antibody
-
2:14
a new classification for identifying high-risk myeloma based on cytogenetic abnormalities
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
4:49
car-t vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
-
4:26
what are bispecific antibodies?
-
1:14
the car t-cell strategy vs bispecific antibodies
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
4:01
determining the optimal sequencing of anti-bcma therapies in multiple myeloma
-
2:45
emerging treatments for myeloma: quadruplets, bispecific antibodies & car t-cells
-
3:38
a look into the future: car-t and bispecifics in myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab